Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ABUS NASDAQ:AMAG NASDAQ:ARCT NASDAQ:AVDL On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABUSArbutus Biopharma$4.38+3.3%$4.02$2.70▼$5.10$843.10M1.09948,716 shs45,367 shsAMAGAMAG Pharmaceuticals$13.75$13.74$4.41▼$13.80$477.47M0.89950,664 shsN/AARCTArcturus Therapeutics$21.78+2.5%$18.25$8.04▼$23.59$590.62M2.39519,878 shs160,180 shsAVDLAvadel Pharmaceuticals$14.65+2.0%$14.69$6.38▼$16.66$1.42B1.461.35 million shs80,050 shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABUSArbutus Biopharma-0.93%-1.17%-4.93%+35.46%+9.84%AMAGAMAG Pharmaceuticals0.00%0.00%0.00%0.00%0.00%ARCTArcturus Therapeutics+9.59%+3.81%+22.69%+65.37%+1.58%AVDLAvadel Pharmaceuticals+1.20%-0.69%-6.69%+34.93%+9.11%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABUSArbutus Biopharma$4.38+3.3%$4.02$2.70▼$5.10$843.10M1.09948,716 shs45,367 shsAMAGAMAG Pharmaceuticals$13.75$13.74$4.41▼$13.80$477.47M0.89950,664 shsN/AARCTArcturus Therapeutics$21.78+2.5%$18.25$8.04▼$23.59$590.62M2.39519,878 shs160,180 shsAVDLAvadel Pharmaceuticals$14.65+2.0%$14.69$6.38▼$16.66$1.42B1.461.35 million shs80,050 shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABUSArbutus Biopharma-0.93%-1.17%-4.93%+35.46%+9.84%AMAGAMAG Pharmaceuticals0.00%0.00%0.00%0.00%0.00%ARCTArcturus Therapeutics+9.59%+3.81%+22.69%+65.37%+1.58%AVDLAvadel Pharmaceuticals+1.20%-0.69%-6.69%+34.93%+9.11%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceABUSArbutus Biopharma 2.50Moderate Buy$5.0014.16% UpsideAMAGAMAG Pharmaceuticals 0.00N/AN/AN/AARCTArcturus Therapeutics 2.90Moderate Buy$50.57132.25% UpsideAVDLAvadel Pharmaceuticals 2.70Moderate Buy$20.8642.35% UpsideCurrent Analyst Ratings BreakdownLatest AVDL, AMAG, ARCT, and ABUS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/13/2025ARCTArcturus TherapeuticsZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Strong-Buy10/10/2025ARCTArcturus TherapeuticsCitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy10/8/2025ABUSArbutus BiopharmaWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025ARCTArcturus TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025AVDLAvadel PharmaceuticalsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)10/7/2025AVDLAvadel PharmaceuticalsZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold9/27/2025ABUSArbutus BiopharmaWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025ARCTArcturus TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025AVDLAvadel PharmaceuticalsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/5/2025AVDLAvadel PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$24.00 ➝ $36.009/4/2025ARCTArcturus TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$60.00(Data available from 10/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookABUSArbutus Biopharma$6.17M136.09N/AN/A$0.51 per share8.59AMAGAMAG Pharmaceuticals$327.75M1.46N/AN/A$7.37 per share1.87ARCTArcturus Therapeutics$109.80M5.39N/AN/A$8.90 per share2.45AVDLAvadel Pharmaceuticals$221.08M6.44N/AN/A$0.77 per share19.03Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateABUSArbutus Biopharma-$69.92M-$0.29N/AN/AN/A-352.24%-59.28%-44.11%11/5/2025 (Estimated)AMAGAMAG Pharmaceuticals-$466.46M-$6.88N/A76.39N/A-74.93%-16.92%-5.96%N/AARCTArcturus Therapeutics-$80.94M-$2.23N/AN/AN/A-49.26%-24.87%-17.75%11/6/2025 (Estimated)AVDLAvadel Pharmaceuticals-$48.83M-$0.03N/A244.20N/A-1.32%-3.73%-1.73%11/11/2025 (Estimated)Latest AVDL, AMAG, ARCT, and ABUS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails11/11/2025Q3 2025AVDLAvadel Pharmaceuticals$0.08N/AN/AN/AN/AN/A11/6/2025Q3 2025ARCTArcturus Therapeutics-$1.09N/AN/AN/A$17.47 millionN/A11/5/2025Q3 2025ABUSArbutus Biopharma-$0.0460N/AN/AN/A$1.31 millionN/A8/11/2025Q2 2025ARCTArcturus Therapeutics-$1.11-$0.34+$0.77-$0.34$17.64 million$28.30 million8/7/2025Q2 2025AVDLAvadel Pharmaceuticals$0.02$0.10+$0.08$0.10$60.28 million$68.13 million8/6/2025Q2 2025ABUSArbutus Biopharma-$0.02$0.01+$0.03$0.01$2.21 million$10.74 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthABUSArbutus BiopharmaN/AN/AN/AN/AN/AAMAGAMAG PharmaceuticalsN/AN/AN/AN/AN/AARCTArcturus Therapeutics$0.713.28%N/AN/A N/AAVDLAvadel PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioABUSArbutus BiopharmaN/A20.5320.53AMAGAMAG Pharmaceuticals1.131.751.45ARCTArcturus TherapeuticsN/A5.905.90AVDLAvadel PharmaceuticalsN/A2.792.38Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipABUSArbutus Biopharma43.79%AMAGAMAG PharmaceuticalsN/AARCTArcturus Therapeutics94.54%AVDLAvadel Pharmaceuticals69.19%Insider OwnershipCompanyInsider OwnershipABUSArbutus Biopharma20.30%AMAGAMAG Pharmaceuticals12.73%ARCTArcturus Therapeutics15.30%AVDLAvadel Pharmaceuticals5.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableABUSArbutus Biopharma90191.70 million152.78 millionOptionableAMAGAMAG Pharmaceuticals44034.73 millionN/AOptionableARCTArcturus Therapeutics18027.16 million23.00 millionOptionableAVDLAvadel Pharmaceuticals7097.10 million92.05 millionOptionableAVDL, AMAG, ARCT, and ABUS HeadlinesRecent News About These CompaniesAvadel Pharmaceuticals (NASDAQ:AVDL) Stock Passes Above 200-Day Moving Average - Should You Sell?October 14 at 3:35 AM | americanbankingnews.comAvadel Pharmaceuticals (NASDAQ:AVDL) Shares Pass Above 200-Day Moving Average - Time to Sell?October 14 at 3:34 AM | marketbeat.comAvadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)October 13 at 4:05 PM | globenewswire.comAvadel Pharmaceuticals (NASDAQ:AVDL) Downgraded to Hold Rating by Zacks ResearchOctober 10, 2025 | marketbeat.comQ3 Earnings Forecast for AVDL Issued By Leerink PartnrsOctober 10, 2025 | marketbeat.comAvadel Pharmaceuticals (NASDAQ:AVDL) Given Sell (E+) Rating at Weiss RatingsOctober 9, 2025 | marketbeat.comAnalysts Expect Avadel Pharmaceuticals plc (NASDAQ:AVDL) To Breakeven SoonOctober 5, 2025 | finance.yahoo.comAvadel Pharmaceuticals (NASDAQ:AVDL) Stock Rating Upgraded by Wall Street ZenSeptember 28, 2025 | marketbeat.comAvadel Pharmaceuticals PLC. (NASDAQ:AVDL) Given Consensus Rating of "Buy" by AnalystsSeptember 28, 2025 | marketbeat.comWall Street Zen Downgrades Avadel Pharmaceuticals (NASDAQ:AVDL) to BuySeptember 20, 2025 | marketbeat.comAnalysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY) and Avadel Pharmaceuticals (AVDL)September 19, 2025 | theglobeandmail.comAvadel says court requires 3.85% of Lumryz sales go to JazzSeptember 17, 2025 | msn.comGoldman Sachs Group Inc. Has $5.70 Million Position in Avadel Pharmaceuticals PLC. $AVDLSeptember 17, 2025 | marketbeat.comAvadel Pharmaceuticals (NASDAQ:AVDL) Shares Down 3.7% - Time to Sell?September 16, 2025 | marketbeat.comAvadel Pharmaceuticals Celebrates Five Years of Driving Growth in Sleep Research FundingSeptember 16, 2025 | globenewswire.comWoodline Partners LP Buys 395,040 Shares of Avadel Pharmaceuticals PLC. $AVDLSeptember 15, 2025 | marketbeat.comAvadel: LUMRYZ Momentum And Pipeline Expansion Support Buy RatingSeptember 12, 2025 | seekingalpha.comAvadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)September 10, 2025 | globenewswire.comAvadel Pharmaceuticals Plc (AVDL) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)September 9, 2025 | seekingalpha.comAvadel licenses valiloxybate in bid to expand sleep disorder pipelineSeptember 8, 2025 | thepharmaletter.comTAvadel (AVDL) Licenses Valiloxybate and Unveils LUMRYZ Data at World Sleep 2025September 8, 2025 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeAVDL, AMAG, ARCT, and ABUS Company DescriptionsArbutus Biopharma NASDAQ:ABUS$4.38 +0.14 (+3.30%) As of 10:30 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression. The company's research and development programs include AB-101, an oral PD-L1 inhibitor to reawaken patients' HBV-specific immune system; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has licensing agreements with Gritstone Oncology, Inc; Alnylam Pharmaceuticals, Inc.; Qilu Pharmaceuticals Co, Ltd; Assembly Biosciences, Inc.; Acuitas Therapeutics, Inc.; and Antios Therapeutics, Inc. Arbutus Biopharma Corporation also has a clinical collaboration agreement with Barinthus Biotherapeutics plc to evaluate VTP-300. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.AMAG Pharmaceuticals NASDAQ:AMAGAMAG Pharmaceuticals, Inc., a pharmaceutical company, develops, manufactures, and commercializes therapeutics for maternal and women's health, and anemia management in the United States. The company markets Feraheme (ferumoxytol), an intravenous iron replacement therapeutic agent for the treatment of iron deficiency anemia in adult patients who have intolerance to oral iron or have had unsatisfactory response to oral iron, as well as patients who have chronic kidney disease; Makena, a hydroxyprogesterone caproate injection to reduce the risk of preterm birth in women pregnant with a single baby who have a history of singleton spontaneous preterm birth; Intrarosa(prasterone) vaginal insert steroid for the treatment of dyspareunia due to menopause; and Vyleesi (bremelanotide), an auto-injector device for the treatment of hypoactive sexual desire disorder in pre-menopausal women. Its product candidates also include AMAG-423 (ovine), an antibody fragment, which is in Phase 2b/3a trial for the treatment of severe preeclampsia in pregnant women; and Ciraparantag, an anticoagulant reversal agent that is in planned Phase 2b trial for the treatment of novel oral anticoagulants or low molecular weight heparin. The company sells Feraheme to authorized wholesalers and specialty distributors. The company has license agreements with Endoceutics, Inc., Palatin Technologies, Inc., Velo Bio, LLC, Prasco, LLC, Perosphere Pharmaceuticals Inc., and Antares Pharma, Inc. AMAG Pharmaceuticals, Inc. was founded in 1981 and is headquartered in Waltham, Massachusetts.Arcturus Therapeutics NASDAQ:ARCT$21.78 +0.53 (+2.47%) As of 10:29 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Arcturus Therapeutics Holdings Inc., a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA. The company is developing ARCT-810 (LUNAR-OTC), a mRNA-based therapeutic candidate, which is in Phase 2 clinical trial for treating ornithine transcarbamylase deficiency; and ARCT-154 (LUNAR-COV19), a mRNA vaccine candidate that is in Phase 3 arm of a Phase 1/2/3 study in Vietnam for the treatment of COVID-19, as well as ARCT-032 (LUNAR-CF), a mRNA therapeutic candidate for cystic fibrosis. Its product pipeline includes, ARCT-2301 for bivalent: ancestral/omicron which is in Phase 3; ARCT-2303 for monovalent that is in Phase 3; ARCT-2138 for quadrivalent which is in Phase 1; and LUNAR-FLU which is in pre-clinical trial. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California.Avadel Pharmaceuticals NASDAQ:AVDL$14.65 +0.28 (+1.96%) As of 10:30 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness or cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas 3 Healthcare Companies Insiders Are Buying NVIDIA Analysts Lift Targets: What It Means for the Stock Price Fastenal Stock Pulls Back in October—Is It Time to Buy FAST? 5 Stocks and ETFs to Weather Volatility as Trade Tensions Rise Why Congress Is Buying Intuitive Surgical Ahead of Earnings D-Wave: Reevaluating the Short Seller’s Case After the Downgrade 3 Dividend Hikes That Signal Renewed Strength in 2025 2 Reasons Absci Could Be the Future of AI Biotech, and 1 Risk Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
